Why is Omnipod® 5 the #1 prescribed Automated Insulin Delivery (AID) System in the U.S.?1
The honest answer is we don’t know exactly why, but we have some ideas.
Simplicity
Omnipod 5 is the only tubeless AID in the U.S. It is indicated for people with type 1 diabetes aged 2 years and older and was designed to simplify life for them and diabetes management for you and your care team. This means:
- Waterproof design, offering patients an on-body experience.2
- No need to disconnect from therapy during showering, swimming, sports, intimacy or any other activities of daily living.3
- Caregivers can remotely administer boluses via the Controller or compatible smartphone4 without needing to interrupt play.
- The SmartBolus calculator simplifies mealtime bolus math by including the sensor trend in its bolus suggestion.
- Automatic wireless data uploads help you make clinical decisions with confidence.5
- SmartAdjust™ technology adjusts the basal rate automatically based on the patients’ total daily insulin (TDI).
Clinical Results
We believe simplicity leads to results. Omnipod 5 delivers clinical results in both, pivotal clinical trials and real-world evidence.
- Brown et al. showed that Omnipod 5 improved time in range (TIR) by 9.3% (2.2 hours per day) in adults/adolescents and by 15.6% (3.7 hours per day) in children.6
- Sherr et al. showed that Omnipod 5 improved TIR of very young children (aged 2-5.9) by 10.9% (2.6 hours per day).7
More recently, Forlenza et al. conducted a real-world data analysis of nearly 70,000 Omnipod 5 patients, representing 17.7 million days of use in a non-clinical setting.8 This is the largest published U.S. data set in the current AID landscape.8 The authors concluded that glycemic results from this “large and diverse sample … demonstrate effective use of the Omnipod 5 System under real-world conditions.”8 Results of note include:
- Former MDI patients had a 70.8% TIR and time <70mg/dL was 0.96% at an average target of 110mg/dL.9
- The Medicare insurance cohort (median age 67 years) had a median TIR of 72.3% and time <70 mg/dL of 0.91% at an average target of 110 mg/dL.10 This finding is especially useful for HCPs who might be hesitant to give older patients cutting-edge technology.
- Overall TIR for the full cohort was almost 70% with only 1.12% of time spent in hypoglycemia at an average target of 110 mg/dL.11
- Average time in automated mode was nearly 94%, as patients don’t have to disconnect during daily activities.12,3
You can learn more about the Real-World Evidence study here.
Access
The simplest, most efficacious therapy would be of little use if patients couldn’t access it. This is why you can prescribe Omnipod the same way as prescribing insulin, without DME hurdles.
- Omnipod 5 is available through the pharmacy so that patients aren’t locked into a four-year DME warranty. Your patients can get started today.13
- Over 90% insurance coverage, representing over 300 million covered lives and we keep working to expand this number.14
- More than half of covered Omnipod 5 scripts are filled within 24 hours through the pharmacy.15
- The majority of Omnipod 5 customers pay $50 or less per month.16
Learn more about prescribing Omnipod 5.
- USA 2023. Data on file.
- The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Controller is not waterproof.
- Device components including the Pod, CGM transmitter, and CGM sensor may be affected by strong radiation or magnetic fields. Device components must be removed (and the Pod and CGM sensor should be disposed of) before X-ray, Magnetic Resonance Imaging (MRI), or Computed Tomography (CT) scan (or any similar test or procedure). In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to X-ray, MRI, or CT, treatment can damage these components. Check with your healthcare provider on Pod removal guidelines.
- For a list of compatible smartphone devices visit omnipod.com/compatibility.
- Must be connected to WiFi or cellular data, and Omnipod 5 users must have WiFi or cellular data access to receive updates in Glooko.
- Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 – 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time 70-180mg/dL as measured by CGM in adults/adolescents and children, ST vs. Omnipod 5: 64.7% vs. 73.9%, P<0.0001; 5% vs. 68.0%, P<0.0001, respectively.
- Sherr JL, et al. Prospective trial in 80 participants with T1D aged 2 – 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (70-180mg/dL) in very young children (2 – 5.9 yrs) as measured by CGM: ST = 57.2%, 3-mo Omnipod 5 = 68.1%, P<0.05. Mean HbA1c: ST vs. Omnipod 5 use in very young children (2 – 5.9 yrs) 7.4% vs 6.9%, P<0.05. Median time in hypoglycemic range (<70 mg/dL) as measured by CGM: ST vs. Omnipod 5 use in very young children (2 – 5.9 yrs) (3.43% vs. 2.46%, P=0.0204).
- Forlenza G, et al. Real-world evidence of Omnipod 5 Automated Insulin Delivery System use in 69,902 people with type 1 diabetes. Diabetes Technol Ther. 2024.
- Forlenza G, et al. Diabetes Technol Ther (2024). 6,525 Omnipod 5 users with type 1 diabetes at the Target Glucose of 110 mg/dL who utilized MDI as prior therapy had a time in range of 70.8% and a TBR of 0.96%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.
- Forlenza G, et al. Diabetes Technol Ther (2024). 61,503 Omnipod 5 users with type 1 diabetes at the Target Glucose of 110 mg/dL who had Medicare insurance had a time in range of 72.3% and a TBR of 0.91%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.
- Forlenza G, et al. Diabetes Technol Ther (2024). Real-world data from 37,640 Omnipod 5 users with type 1 diabetes at the Target Glucose of 110 mg/dL had a median TIR (70-180 mg/dL) of 68.8% and a median TBR of 1.12%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.
- Forlenza G, et al. Real-world evidence of Omnipod 5 Automated Insulin Delivery System use in 69,902 people with type 1 diabetes resulted in 93.7% time in Automated Mode. Diabetes Technol Ther. 2024
- Only available for users with valid prescription and coverage through their pharmacy benefit. Exact coverage depends on patient’s insurance plan. Upgrades subject to user’s insurance coverage.
- Reflects coverage for Omnipod 5 G6 Intro Kit and Omnipod 5 G6 Pods. Source: Insulet Data on File As of June 1 2023.
- Calculated based on a consumption of ten (10) Pods per month. Majority defined as at least 70% of patient co-pays $50 or less per month . Among All Paid Omnipod 5 G6 Pods Commercial and Medicare Claims from August 2022 through July 2023. Includes benefits and offerings available through Insulet, such as the copay card program. Actual co-pay amount depends on patient’s health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis. Source: IQVIA OPC Library. Calculated based on a consumption of ten (10) Pods per month. Among All Paid Omnipod 5 G6 Pods Commercial and Medicare Claims from August 2022 through July 2023. Includes benefits and offerings available through Insulet, such as the copay card program. Actual co-pay amount depends on patient’s health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis. Source: IQVIA OPC Library
- Calculated based on the proportion of script fills within 24-hour look forward period out of all script fills within a 90-day look forward period among all new to brand claims for the Omnipod 5 G6 Intro Kit from October 2022 to March 2023. Excludes claim reversals. Source: IQVIA Payer Control Library